116 related articles for article (PubMed ID: 27321103)
1. [Erythropoietin and drug resistance in breast and ovarian cancers].
Szenajch JM; Synowiec AE
Ginekol Pol; 2016; 87(4):300-4. PubMed ID: 27321103
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S
Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814
[TBL] [Abstract][Full Text] [Related]
3. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.
Hedley BD; Chu JE; Ormond DG; Beausoleil MS; Boasie A; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(19):6151-62. PubMed ID: 21856770
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Gewirtz DA; Di X; Walker TD; Sawyer ST
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.
Paragh G; Kumar SM; Rakosy Z; Choi SC; Xu X; Acs G
Am J Pathol; 2009 Apr; 174(4):1504-14. PubMed ID: 19264915
[TBL] [Abstract][Full Text] [Related]
8. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review.
Szenajch J; Wcislo G; Jeong JY; Szczylik C; Feldman L
Biochim Biophys Acta; 2010 Aug; 1806(1):82-95. PubMed ID: 20406667
[TBL] [Abstract][Full Text] [Related]
9. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
10. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells.
Jeong JY; Feldman L; Solar P; Szenajch J; Sytkowski AJ
Int J Cancer; 2008 Jan; 122(2):274-80. PubMed ID: 17893874
[TBL] [Abstract][Full Text] [Related]
11. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen.
Ilkovičová L; Trošt N; Szentpéteriová E; Solár P; Komel R; Debeljak N
Int J Oncol; 2017 Aug; 51(2):737-746. PubMed ID: 28714517
[TBL] [Abstract][Full Text] [Related]
13. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy.
ten Bokkel Huinink WW; de Swart CA; van Toorn DW; Morack G; Breed WP; Hillen HF; van der Hoeven JJ; Reed NS; Fairlamb DJ; Chan SY; Godfrey KA; Kristensen GB; van Tinteren H; Ehmer B
Med Oncol; 1998 Sep; 15(3):174-82. PubMed ID: 9819794
[TBL] [Abstract][Full Text] [Related]
14. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin receptor function and expression in epithelial ovarian carcinoma.
McBroom JW; Acs G; Rose GS; Krivak TC; Mohyeldin A; Verma A
Gynecol Oncol; 2005 Dec; 99(3):571-7. PubMed ID: 16051335
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma.
Acs G; Zhang PJ; Rebbeck TR; Acs P; Verma A
Cancer; 2002 Sep; 95(5):969-81. PubMed ID: 12209679
[TBL] [Abstract][Full Text] [Related]
17. The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.
Hu W; Zhang Y; Jiang Z; Wang L; Li J; Chen S; Dai N; Si J
Tumour Biol; 2016 Aug; 37(8):11523-33. PubMed ID: 27086036
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin Stimulates Tumor Growth via EphB4.
Pradeep S; Huang J; Mora EM; Nick AM; Cho MS; Wu SY; Noh K; Pecot CV; Rupaimoole R; Stein MA; Brock S; Wen Y; Xiong C; Gharpure K; Hansen JM; Nagaraja AS; Previs RA; Vivas-Mejia P; Han HD; Hu W; Mangala LS; Zand B; Stagg LJ; Ladbury JE; Ozpolat B; Alpay SN; Nishimura M; Stone RL; Matsuo K; Armaiz-Peña GN; Dalton HJ; Danes C; Goodman B; Rodriguez-Aguayo C; Kruger C; Schneider A; Haghpeykar S; Jaladurgam P; Hung MC; Coleman RL; Liu J; Li C; Urbauer D; Lopez-Berestein G; Jackson DB; Sood AK
Cancer Cell; 2015 Nov; 28(5):610-622. PubMed ID: 26481148
[TBL] [Abstract][Full Text] [Related]
19. Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.
Patterson SD; Rossi JM; Paweletz KL; Fitzpatrick VD; Begley CG; Busse L; Elliott S; McCaffery I
PLoS One; 2015; 10(3):e0122149. PubMed ID: 25807104
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
Mannello F; Tonti GA
Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
